Full Breakdown
Merck and Moderna Report Positive Phase 3 Interim Results for Personalized Melanoma Vaccine
8/20/2026, 12:32:08 AM
Trial Results and Primary Findings (Core Event)
On August 19, the companies announced that the experimental personalized mRNA vaccine Intismeran, given with Merck’s immunotherapy Keytruda, met its primary endpoint of extending recurrence-free survival (RFS) and also achieved the secondary endpoint of improving distant-metastasis-free survival (DMFS) in patients whose high-risk melanoma had been surgically removed. Volunteers received up to nine combined doses over roughly one year, and the interim analysis showed statistically significant improvements compared with Keytruda alone. No new safety signals were reported.
Background and Development
Merck and Moderna began collaborating on a personalized cancer-vaccine platform in 2016. The approach sequences each patient’s tumor, selects up to 34 neo-antigens, and encodes them into an mRNA construct that trains the immune system to recognize those mutations. Earlier Phase 2 data presented in June demonstrated a 49 % reduction in five-year recurrence risk when the vaccine was added to Keytruda. The current Phase 3 study, INTerpath-001, is the first late-stage trial to test an individualized mRNA cancer therapy.
Data and Statistics
- Enrollment: 1,137 patients with stage IIB-IV cutaneous melanoma whose tumors were completely resected.
- Design: Randomized 1:1 to Keytruda + Intismeran versus Keytruda alone; up to nine doses over ~12 months.
- Efficacy: Interim analysis indicated a statistically significant extension of RFS and DMFS.
- Safety: No new adverse events beyond those previously observed.
- Market reaction: Moderna’s share price surged between 90 % and 150 % in pre-market trading, while Merck’s stock rose roughly 7 %–11 % in early trading.
Official Statements & Responses
The companies said the data will be presented at an upcoming oncology conference and that regulatory discussions are already underway. Moderna’s president Stephen Hoge noted that, given the therapy’s breakthrough-therapy designation, approval could be possible as early as the following year. Merck’s research head Dean Li added that the partners expect to begin formal regulator talks “in the next few months.” Both firms emphasized that the trial will continue to collect overall-survival data.
Criticism & Opposition
Oncologists highlighted caveats. Dr. Marcus Butler said the trial’s focus on early-stage disease and the lack of a placebo “dummy vaccine” make it difficult to separate the specific effect of the neo-antigen vaccine from general mRNA immune stimulation. Dr. Falyn Katz of Melanoma Canada noted that “we are still losing three people every day in Canada to melanoma.”
Conflicting Reports & Gaps
Sources differ on the magnitude of share-price gains: some report a 90 % jump for Moderna, others cite 106 % or 150 %. The exact quantitative reduction in recurrence risk for the Phase 3 interim data was not disclosed; only “statistically significant” improvement is mentioned. Overall-survival outcomes remain pending, and the manufacturing scalability of a patient-specific mRNA product has not been quantified.
Why It Matters
If approved, Intismeran would become the first mRNA-based cancer therapy to succeed in a Phase 3 trial, validating a platform that could be adapted to other solid tumors. The result offers a new adjuvant option for melanoma patients, a disease that accounts for the majority of skin-cancer deaths despite representing only 1 % of skin-cancer cases. For Moderna, the breakthrough provides a growth catalyst beyond COVID-19 vaccines; for Merck, it diversifies the Keytruda franchise ahead of an anticipated patent expiry later this decade.
